Targeted molecular therapies comprise the newest frontier of oncology research. [1] [2] [3] Recent investigations have concentrated on the development of novel treatments designed to interrupt cellular pathways crucial to oncogenesis and, in fact, these medications represent a large proportion of drugs undergoing evaluation in current and new clinical trials.
Humanized antibodies (suffix -zumab) retain the complementary determining regions of the murine precursor, also known as the hypervariable region, with an entirely human underpinning. The final composition is approximately 95% human. 2 Yet another subset of antibody response has been observed: human antihuman antibodies (HAHAs). Again, the frequency of such immune responses is much less than in previous antibody arrangements. Finally, a strategy for the virtual elimination of human hypersensitivity reactions following exposure to engineered monoclonal antibodies involves developing transgenic mice, and these fully human antibodies carry the suffix -mumab. 1, 2 The armamentarium of cancer therapy includes agents from each of these subtypes, which are either under investigation for use in humans or have already been awarded US Food and Drug Administration (FDA) approval for the treatment of certain malignancies.
Epidermal Growth Factor Receptor
Non-malignant cells develop in a regulated fashion using a series of intracellular signaling pathways that dictate typical cellular responses such as angiogenesis, proliferation, and cell survival. Preferential activation of these pathways leads to promotion of tumor growth, invasion, and metastasis. Receptor tyrosine kinase (RTK) activation mediates multiple intracellular signaling pathways, and dysregulation of the activation and expression of the components of this pathway is considered to be one etiology of tumorigenesis. 5 The epidermal growth factor receptor (EGFR) is the gatekeeper of one such critical tyrosine kinase pathway and exemplifies a target for novel chemotherapeutics. In general, cetuximab mediates its action through the inhibition of tumor proliferation, angiogenesis, and metastasis, induction of apoptosis, and/or promotion of cell-cycle arrest. 1, 12 It also serves as a radiosensitizer when used concurrently with traditional chemotherapeutic agents. Cetuximab promotes cell-cycle arrest in the G1 phase, which culminates in cellular apoptosis and leads to overall inhibition of tumor proliferation. In a separate signaling cascade, angiogenesis is interrupted by the inhibited production of angiogenic factors including vascular endothelial growth factor (VEGF). This antiangiogenic activity mediates a decrease in microvessel density of the tumor while advancing endothelial cell apoptosis. 3 Cetuximab may also prevent nuclear transport of EGFR, thereby inhibiting DNA repair mechanisms that address chemo-or radiotherapeutically induced DNA damage. 13 Finally, cetuximab likely participates in antibody-dependent cell-mediated cytotoxicity (ADCC) secondary to its IgG1 structure. 4 Reported toxicities associated with cetuximab include constitutional symptoms such as fevers, chills, fatigue, and nausea, infusion reactions, and hypersensitivity reactions, as well as an acneiform skin rash, reported in some studies in up to 88% of patients. 3 Severity of the rash has been linked in several studies to improved efficacy and therapeutic response. 2 However, cetuximab is, overall, well tolerated. In phase I studies regarding the immunogenicity of cetuximab, fewer than 4% of patients developed HACAs following administration of the medication. 14 Several studies have suggested an association between severity of dermatological toxicity and treatment response to cetuximab. 6 The Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST) trial was designed to evaluate the prognostic value of acneiform rash as a surrogate for treatment response in chemotherapy-refractory metastatic colorectal cancer patients. 15 These patients underwent concurrent cetuximab and irinotecan treatment at typical dose schedules. After three weeks of therapy, patients were assessed for extent of skin involvement, and those not achieving grade 2 skin toxicity were randomized to maintenance of standard-dose cetuximab versus dose escalation until the appearance of grade 2 toxicities or a dose cap was reached. Comparison of the response rates revealed that patients with at least a grade 2 skin toxicity either initially or in response to dose escalation enjoyed higher rates-34 and 30%, respectively-than those patients who did not develop significant skin involvement with standard-dose cetuximab.
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Squamous Cell Cancers of the Head and Neck
Squamous cell carcinomas of the head and neck encompass several primary sites of histologically similar tumors. Approximately 50% of patients can achieve a cure with initial treatment. The most common location for recurrence is locoregional, and local recurrence is a common etiology of death in these patients. 13 Traditional risk factors for these cancers include tobacco products and excessive alcohol use. More recently, as in cervical cancer carcinogenesis, high-risk human papillomavirus (HPV) subtypes have been implicated in the pathogenesis of some of these cancers. HPV-related squamous cell carcinomas of the head and neck also appear to enjoy a better overall prognosis. 13 Similar to recurrent cervical cancers, recurrent head and neck cancers are palliated with single-or double-agent platinum-based chemotherapy until platinum resistance is diagnosed. Initial treatment for these cancers involves surgery with adjuvant chemoradiation, definitive chemoradiation reserving surgery as salvage, or induction chemotherapy with definitive chemoradiation. 13 Furthermore, squamous cell carcinomas of the head and neck have been consistently noted to have >90% overexpression of EGFR, suggesting potential activity for cetuximab in these cancers. 13 Indeed, cetuximab demonstrates efficacy when applied to squamous cell cancers of the head and neck, including enhanced radiosensitivity in vitro, and with preliminary studies confirming activity in the setting of radiotherapy for locoregionally advanced tumors. 
Cervical Cancer
Worldwide, cervical cancer is the second leading cause of cancer deaths in women. 16, 17 Although the incidence in the US has been decreasing over the past two decades secondary to the availability of effective screening programs, cervical cancer remains an important public health concern. women will be diagnosed with cervical cancer and 4,070 women will die from their disease. 18 One-third of those patients presenting with invasive cancer will eventually succumb to their disease, despite innovations in cancer screening and prevention. 17, 19 Early-stage cervical cancers can be treated successfully and with equal efficacy using either radical surgery or radiation. 20 However, approximately 25% of women have advanced disease at diagnosis, and the overall survival for these patients is low, even with multimodality therapies. 9 Furthermore, despite investigated for the treatment of advanced and recurrent cervical cancers with a reported response rate of 38%. 19 Overall survival using cisplatin in this setting was demonstrated to be seven months. 17 Since that time, various agents have been evaluated for response in the setting of recurrent or advanced disease, 17, 24 and of the 21
demonstrating efficacy with response rates of at least 15%, the five yielding the greatest activity include cisplatin, paclitaxel, topotecan, vinorelbine, and ifosfamide. In an effort to further improve treatment efficacy, several studies have assessed the effect of adding additional cytotoxic agents to the cisplatin-containing doublets; however, none of these so-called triplets have shown improvement over cisplatin-based mono-or doublet therapy. 17, 19 Given the limitations of effective traditional chemotherapy regimens for advanced and recurrent cervical cancer, focus has necessarily moved to the new frontier of biologic therapy.
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Epidermal Growth Factor Receptor and Cervical Cancer
The precise role of EGFR in cervical cancer has been an ongoing investigation. 9 While early studies demonstrated overexpression in cervical cancers and cervical intraepithelial neoplasia similar to that found in other solid tumors, later research provided less convincing data, noting only a small percentage of differential expression of EGFR in malignant versus healthy cervical epithelium. 9 In fact, the reported range of EGFR overexpression in cervical cancers is wide-6-85% 
Conclusion
In the setting of advanced and recurrent cervical cancers, traditional therapies with the best efficacy still provide response rates of only 17-38%. 
